Key terms
About AUTL
Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest AUTL news
Apr 12
6:06am ET
Buy Rating on Autolus Therapeutics: Innovative Cancer Treatments and Strategic Leadership Drive Positive Outlook
Apr 02
7:16am ET
Autolus Therapeutics announces acceptance of MAA by EMA for obe-cel
Apr 01
7:22am ET
Autolus Therapeutics Announces Board Leadership Changes
Apr 01
7:19am ET
Autolus chairman John Johnson steps down, Mike Bonney succeeds
Mar 28
4:22pm ET
Autolus files to sell 33.33M American Depositary Shares for holders
Mar 25
8:41am ET
Aveo Oncology appoints Edgar Braendle as CMO
Mar 18
9:22am ET
Autolus Therapeutics price target raised to $10 from $9 at Truist
Mar 14
1:40pm ET
Analysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM), Coherus Biosciences (CHRS) and Autolus Therapeutics (AUTL)
Mar 14
12:42pm ET
Autolus Therapeutics Announces Annual Results and CDO Resignation
Mar 12
7:28am ET
Autolus Therapeutics receives MHRA certification for Nucleus site
Mar 11
7:08am ET
Autolus Therapeutics announces publication in Blood Cancer Journal
Feb 22
7:21am ET
Autolus Therapeutics announces publication in Nature Communications
Feb 13
4:26pm ET
Autolus Therapeutics Shares Updated Corporate Insights
Feb 12
6:35am ET
Autolus Therapeutics: Strengthened by Strategic Collaboration and Upgraded Price Target
Feb 09
5:20am ET
Analysts’ Top Healthcare Picks: Merck & Company (MRK), Omnicell (OMCL)
Feb 09
4:51am ET
Autolus Therapeutics Announces New Offering Expectations
Feb 09
4:51am ET
Autolus Therapeutics Inks Major $350M Underwriting Deal
Feb 09
4:03am ET
Autolus Therapeutics Announces BioNTech Agreement Details
Feb 09
4:02am ET
Autolus Therapeutics’ Private Placement Raises Capital
Feb 09
4:02am ET
Autolus Therapeutics Strikes Major Deal with BioNTech
Feb 08
5:35pm ET
Neutral Outlook for Autolus Therapeutics Amid BioNTech Collaboration and Reduced M&A Speculation
Feb 08
7:19am ET
Autolus Therapeutics prices 58.3M ADSs at $6.00 in underwritten public offering
Feb 08
6:05am ET
Autolus Therapeutics files automatic mixed securities shelf
Feb 08
5:49am ET
BioNTech, Autolus Therapeutics announce strategic alliance
Jan 27
4:13am ET
Autolus Therapeutics’ CAR T Therapy FDA Application Accepted
Jan 23
7:03am ET
Autolus Therapeutics announces publication in ACS Chemical Biology
Jan 23
6:08am ET
Wells Fargo Gives a Buy Rating to Autolus Therapeutics (AUTL)
Jan 22
7:45pm ET
Autolus Therapeutics Poised for Growth: Buy Rating and $12 Price Target Backed by Strong Pipeline and Regulatory Milestones
Jan 22
2:47pm ET
Buy Rating Reiterated for Autolus Therapeutics Amid Positive Regulatory Developments and Growth Potential
Jan 22
7:05am ET
Autolus Therapeutics announces acceptance of BLA for obe-cel
No recent press releases are available for AUTL
AUTL Financials
Key terms
Ad Feedback
AUTL Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
AUTL Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range